Ahead of Print
Miopatia Tóxica Associada à Interação Sinvastatina–Claritromicina Durante Terapêutica de Erradicação de Helicobacter Pylori: Relato De Caso
Toxic Myopathy Associated with Simvastatin–Clarithromycin Interaction During Helicobacter Pylori Eradication Therapy: A Case Report
Main Article Content
Eduardo Martins - ehdmartins@gmail.com
Unidade de Saúde Familiar Corgo, Unidade Local de Saúde Trás-os-Montes e Alto Douro, Vila Real, Portugal.
Rua Dr. Manuel Cardona, 5000-557 Vila Real
Abstract
Helicobacter pylori infection has a high prevalence in Portugal and its eradication is a crucial measure in the prevention of gastric cancer. Clarithromycin-based eradication regimens continue to be frequently used in clinical practice.
We present a case of a patient who developed severe toxic myopathy associated with the co-administration of simvastatin and clarithromycin, prescribed as part of an Helicobacter pylori eradication regimen.
This case reinforces the importance of a thorough review of patients’ usual medication before starting new therapies and the need for vigilance regarding predictable drug interactions, particularly those involving statins and drugs that inhibit their metabolismo.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.